Decoy20 Enrollment Halted as Indaptus Winds Down Clinical Work
INDP has more than doubled off its 52-week low of $0.92 on light trading volume (0.1× avg).
Summary
Indaptus has stopped enrolling patients in its Decoy20 combination study and wound down the related clinical work, leaving no patients in active trials while it reassesses strategy. That is the material new fact here — the $24.0 million private placement it completed was already disclosed in the September 10 8-K, and the Q3 10-Q filed November 13 noted no active clinical program. The company now says the placement proceeds will fund operations and exploratory research into a sleep device, a sharp pivot away from the immunotherapy pipeline that defined the thesis. With the going-concern doubt resolved on $26.6 million in cash plus $4.0 million in CDs and $3.5 million received in October, the balance sheet buys time, but there is no clinical readout left to trade against.
At the time of this announcement, INDP was trading at $3.10 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $486.9M. The 52-week trading range was $0.92 to $5.96. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: Wiseek News.